FDA’s PDUFA goal date is November 1, 2026; If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell disease; CAMBRIDGE, Mass., Ju ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results